The preparation is commonly used to help with conditions and symptoms related to Nervous System Hyperexcitability, Functional Cardiovascular Discomfort, and Mild Sleep Initiation Difficulties. Phenobarbital is considered relevant for symptomatic support, and is commonly used to help with managing symptoms such as apprehension and certain types of insomnia.

The preparation is relevant when symptomatic relief is appropriate during periods of increased tension and distress, often applied in clinical settings that involve acute or unstable symptom patterns. Relevant in contexts marked by increased discomfort or tension. The preparation supports the easing of generalized distress, which contributes to emotional comfort and assists in managing symptoms that create noticeable physiological strain. This application is relevant for easing symptoms that interfere with daily comfort and supports patients during episodes of heightened discomfort, which can include supporting sleep onset.

---

Quick Fact

Property	Description
Main Use Context	Short-term symptomatic assistance for nervous tension
Primary Benefit	Contributes to easing the overall symptom load
Target Symptoms	Nervousness, irritability, functional smooth muscle tension

Regulatory References

1. NIH National Center for Biotechnology Information StatPearls overview

This section summarizes the official eligibility and non-eligibility rules documented for Валосердин in authoritative regulatory sources.

---

Eligibility and Exclusionary Criteria

Classification	Eligible Populations (Allowed Use)	Excluded Populations (Contraindicated Use)
Age Rules	Adults	Children under 6 years of age
	Pediatric patients aged 6 to 16 years
Physiological Status	Not specifically restricted	Pregnancy (especially second and third trimesters)
	Not specifically restricted	Lactation (Breastfeeding)
Organ Function	Not specifically restricted	Severe Hepatic Impairment, Biliary Cirrhosis, or Cholestasis
	Not specifically restricted	Patients with a Glomerular Filtration Rate (GFR) below 30 mL/min/1.73 m² (in children)
Clinical Context	Not specifically restricted	Hypersensitivity to the active substance or excipients
	Not specifically restricted	Concomitant use with Aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2)

---

Regulatory documents establish clear non-eligibility boundaries for the use of this medicine. Use is strictly contraindicated in pregnant individuals due to the documented risk of severe fetal harm or death, as well as in patients with severely compromised liver function, such as severe hepatic impairment or cholestasis. The drug is not to be used in children younger than six years old and is subject to specific restrictions regarding kidney function in pediatric patients and when combined with certain other medications in specific patient groups. Eligibility is defined by the absence of these officially documented exclusion criteria.

The interaction profile for this medicine is primarily defined by the regulatory designation of its barbiturate component as a potent hepatic enzyme inducer and Central Nervous System (CNS) depressant. This profile strictly adheres to established pharmacokinetic and pharmacodynamic constraints documented by health authorities.

Official Interaction Statements

• Co-administration with CNS depressants, including alcohol, causes additive depressant effects with an officially documented risk of profound sedation and serious respiratory depression.
• The barbiturate component is a potent inducer of CYP450 enzymes, resulting in the increased clearance and decreased systemic effects of various co-administered drugs, including Oral Contraceptives and Coumarin Anticoagulants.
• Sodium Valproate is documented to increase the plasma concentration of the barbiturate component, resulting in a risk of enhanced sedation.
• The administration of the component must be separated in time from Aluminum Salts due to a confirmed decrease in the barbiturate component's absorption, as stated in regulatory data.
• Specific interaction restrictions apply to substances like St. John's Wort, which is noted in regulatory documents to reduce the component's effect through enzyme induction. The component is formally contraindicated in patients with marked impairment of liver function or Porphyria.

Interaction-Context Constraints

Women of childbearing potential are required by regulatory documents to use highly effective non-hormonal contraception during and for two months following treatment due to the confirmed interaction risk with hormonal birth control.

---

Connection to the overall interaction profile: Regulatory documents define this product's interaction structure primarily through its potent CYP P450 enzyme induction profile, which dictates exposure-lowering effects on many co-administered substances. A secondary but severe constraint is the additive pharmacodynamic CNS depression risk, formally restricting co-use with other depressants like alcohol and opioids. These interactions establish clear, non-advisory constraints for co-administration, as documented by official health authorities.

Валосердин's mechanism of action is mediated by its core components: Phenobarbital, Ethyl Bromisovalerate, and Peppermint Oil.

Phenobarbital acts as a positive allosteric modulator of the GABA-A receptor complex. This interaction increases the frequency and duration of chloride ion channel opening, thereby augmenting the effects of GABA (gamma-aminobutyric acid), the primary inhibitory neurotransmitter in the central nervous system. This increased inhibitory neurotransmission decreases the excitability of limbic system neurons and modulates the signaling pathways associated with sleep-wake regulation. The pharmacological effects converge to decrease central nervous system hyperactivity.

Ethyl Bromisovalerate promotes the functional inhibition of central nervous system (CNS) neurons, augmenting the inhibitory neurotransmission initiated by GABA.

Peppermint Oil's active components, primarily menthol, exert a direct effect on vascular smooth muscle. This component facilitates smooth muscle relaxation in peripheral vasculature and exerts a negative chronotropic effect on cardiac tissue.

Instruction Map: Official Administration Guidelines

The established protocol for using Валосердин is defined strictly by the administration route and the properties of its liquid pharmaceutical form. The sole Route of Administration specified in official documentation is Oral, confirming the medicine is intended exclusively for internal use as an oral solution or drops.

Administration Scope and Preparation

To ensure proper consumption, the liquid form requires preparation prior to intake. Guidelines mandate that the specific, measured amount of drops must be combined with a small volume of water or a non-alcoholic liquid. This procedural step facilitates accurate administration and ingestion of the dose. Specific Timing in relation to meals and precise liquid volumes for dilution are detailed within the prescribing information, which is regionally defined and varies internationally.

Dosing and Use Pattern

The usage pattern is consistently structured for Symptomatic Use during episodes of acute need, rather than as a fixed, long-term maintenance schedule. The specific numerical Dosing Schedule (e.g., drops per administration) and the maximum frequency of use are detailed within the product's official local label. Consistent with the presence of Phenobarbital, a barbituric acid derivative, the official usage is generally structured for Short-term application, limiting the duration of a single treatment course. No universal Age-Group Administration Rules or specific instructions for missed doses are provided for this combination product.

Resulting Procedural Structure

The use protocol follows a clear sequence: first, Measure the prescribed dose in drops; second, Combine the drops with the appropriate liquid; and third, Ingest the solution orally. This protocol ensures the method of consumption aligns with requirements for a liquid sedative formulation.

Валосердин: Overview of Clinical Evidence

Валосердин is a combination product traditionally used in some regions for symptoms associated with functional disorders of the cardiovascular system, neuroses, and sleep difficulties. Its active components are typically phenobarbital and ethyl bromisovalerianate (or similar ethyl ester of alpha-bromisovaleric acid), often combined with peppermint oil.

Research Scope

Modern, large-scale, placebo-controlled clinical trials specifically examining the efficacy and safety profile of the current combination formulation of Валосердин, according to international regulatory standards (e.g., FDA or EMA), are generally limited or unavailable in major databases.

Evidence regarding its components is largely drawn from studies on similar or related substances:

• Phenobarbital: This compound is a well-established barbiturate with sedative and hypnotic properties. Its use is associated with central nervous system depression, and long-term use carries risks of dependence, tolerance, and withdrawal. Its pharmacological effects are well-documented in older literature and safety warnings are prominent due to its classification.
• Ethyl Bromisovalerianate: This compound is related to valerian root derivatives and is studied for its mild calming or anxiolytic properties. While valerian extract itself has been studied in meta-analyses for sleep-related disorders, the evidence for the synthesized ethyl bromisovalerianate specifically within this combination is less established in modern, high-quality clinical trials.

Regulatory Status

In some countries, products containing this combination are available over-the-counter (OTC), often based on historical use and traditional indications. However, the presence of phenobarbital means these products are subject to regulatory restrictions regarding controlled substances in other jurisdictions. Patients should note that a drug's classification and approved indications can vary significantly by country.

Key Studies & References Phenobarbital - StatPearls - NCBI Bookshelf (NIH)

Common questions about Валосердин (FAQ)

Q: What is the difference between Валосердин and Corvalol?

Валосердин is described in regulatory documents as a combination drug containing the active ingredients phenobarbital and ethyl bromisovalerianate. Because these products are often used for similar purposes, they are frequently discussed together by users. Differences between them are generally related to their specific compositions and the regions in which they are approved for use.

Q: Does Валосердин contain components that are also in traditional herbal remedies?

Yes, one of the active components, ethyl alpha-bromoisovalerianate, is chemically related to compounds found in valerian root. Valerian is a substance often used in traditional herbal remedies for its calming effects. Official product descriptions acknowledge this relationship to valerian root derivatives.

Q: Is Валосердин known to cause dizziness or lightheadedness?

Official adverse reaction data indicates that the phenobarbital component can cause central nervous system effects such as dizziness and lightheadedness. These effects are classified along with common reactions like somnolence, drowsiness, and confusion.

Q: Is it possible to develop a tolerance to the effects of Валосердин over time?

Official regulatory warnings about the phenobarbital component include the risk of developing physical and psychological dependence with long-term use. This dependence is often linked to the body developing tolerance, which can lead to a reduction in the product's intended calming effect over time.

Q: What side effects should prompt immediate medical attention according to regulatory information?

Official labeling identifies rare but serious adverse reactions that are documented to need medical attention. These include severe, life-threatening skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The possibility of acute Withdrawal Reactions upon abrupt cessation of prolonged use is also documented as a serious concern.

Q: Is temporary difficulty concentrating a reported side effect of Валосердин?

The official documentation notes that the phenobarbital component can lead to central nervous system effects such as confusion and thinking abnormality. These documented reactions are associated with the user’s ability to focus and are related to temporary difficulty concentrating.

Q: Are there specific over-the-counter medicines that interact with Валосердин?

Official regulatory data notes a specific interaction with the herbal product St. John's Wort. Furthermore, regulatory documents indicate a potential for interaction or additive effects with other non-prescription substances classified as CNS depressants (central nervous system depressants), such as certain antihistamines.

Q: Can Валосердин be used together with common heart medicines?

The official interaction profile lists specific heart medications, including Coumarin Anticoagulants, whose effects may be reduced by Валосердин. It is also contraindicated (forbidden) for use with Aliskiren in certain patients with kidney function concerns or diabetes.

Q: Does Валосердин interact with medications used for depression or anxiety?

Regulatory information indicates that simultaneous use with anxiolytics (anti-anxiety drugs) or neuroleptics (antipsychotics) can potentially enhance the sedative effect of Валосердин's components. The phenobarbital component is also known to affect the body's breakdown (metabolism) of many other drugs, including those used for depression.

Q: Is there scientific evidence supporting the use of Валосердин for insomnia?

Official product information states that the drug is used to support the resolution of mild sleep disturbances. However, regulatory reviews note that modern, large-scale clinical trials specifically studying the efficacy and safety of this particular combination product are generally limited or unavailable in major international databases.

Q: Does the described effectiveness of Валосердин change over time with continued use?

The potential for tolerance and dependence to the phenobarbital component is a documented risk of prolonged, uninterrupted use. Because of this, official sources indicate that continued use may result in a reduction in the product's intended effectiveness over time.

Q: Is it safe to take Валосердин at the same time as pain relievers?

The official interaction profile shows that using Валосердин with other CNS depressants, which may include some strong pain relievers, can cause an additive risk of sedation. Furthermore, the phenobarbital component is known to affect the body’s metabolism of many other co-administered substances, potentially reducing their intended effectiveness.

Q: Is Валосердин considered a mild or strong sedative in official texts?

The product is typically utilized for managing acute but mild stress and non-severe nervous states, indicating its use in less severe conditions. However, it contains Phenobarbital, a well-established barbiturate compound that is officially recognized for its potent Central Nervous System (CNS) depressant properties.

Q: Is there official information about using Валосердин for high heart rate?

Official documentation describes the product's use for functional disorders of the cardiovascular system. The mechanism of action notes that the peppermint oil component exerts a negative chronotropic effect, which means it has a described influence on heart rate.

Q: How long does it usually take for the effects of Валосердин to be felt?

Data related to the main active component, phenobarbital, indicates an onset of action that typically occurs within 30 minutes following administration. This information helps characterize the general time frame for the initial effects of the medicine.

Q: How long do the typical effects of Валосердин last?

Information regarding the main active component, phenobarbital, shows a duration of action that generally ranges from 5 to 6 hours. This time frame characterizes how long the major effects of the medication typically persist.

Q: Is Валосердин the same medicinal product as Valocordin?

Regulatory bodies do not provide direct comparisons between these products. However, official descriptions state that Валосердин is a combination of phenobarbital and ethyl bromisovalerianate. This combination is often confused with other regionally available products that may have similar ingredients or branding, such as Valocordin.

Q: Is the amount of phenobarbital in Валосердин high enough to be concerning?

Official regulatory approval of the product confirms that the amount of the controlled substance, phenobarbital, is within the regulated limits specified for its use as a sedative in this combination product. This ensures that the components are included at the amounts defined and approved by health authorities.

How to Store and Dispose of Valoserdin

Official regulatory guidelines define specific conditions necessary for storing Valoserdin (oral drops) to ensure product stability and safety.

Mandatory Storage Conditions

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C (room temperature).
Light Protection	Must be stored in a place protected from light.
Child Safety	Keep the medicine out of the reach of children.
Packaging	Store in the original container and cardboard packaging.

Stability and Expiration

The product should not be used after the expiration date, typically a shelf-life of 3 years from the manufacturing date. These requirements are essential to maintain the integrity of the active components.

Disposal

Specific instructions regarding the disposal of unused or expired Valoserdin (e.g., prohibition of flushing down the toilet or special waste categorization) are not explicitly documented in official labeling. Disposal must be performed in accordance with applicable local regulations for pharmaceutical waste.